Yunnan Baiyao（Chinese：云南白药） released the 2023 semi-annual performance forecast on the morning of July 13, 2023. It is expected that the company will achieve a Net Profit of CNY 2.613 billion(USD 404.85 million) to CNY 3.006 billion(USD 465.97 million) in the first half of the year, a year-on-year increase of 74% to 100%; after deducting non-recurring gains and losses , the Net Profit CNY 2.529 billion(USD 394.23 million）to CNY 2.909 billion(USD 452.27 million）, a year-on-year increase of 53% to 76%.
Yunnan Baiyao was founded in 1902. It integrates brand, product and company name. It is recognized in the industry as the most innovative representative of China's time-honored brands. The brand value is more than CNY 30 billion(USD 4.66 billion）, ranking the top 4 pharmaceutical companies in the country and the first in traditional Chinese medicine. In July 2021, it was selected as one of the top 25 pharmaceutical brand values in the world, was rated as the strongest pharmaceutical brand in China, and was selected as the 34th global pharmaceutical company in 2021.
According to the data of Yunnan Baiyao's official website, the company currently has 247 varieties of proprietary Chinese medicines, involving a total of 354 approvals, of which 43 are exclusive proprietary Chinese medicines and 53 are exclusive approvals. On the one hand, the company vigorously promotes the secondary development of traditional Chinese medicine varieties, and on the other hand promotes the innovation of traditional Chinese medicine products with R & D investment and scientific and technological strength. In terms of the secondary development of traditional Chinese medicine products, the company promoted the research on hemostatic and anti-inflammatory effects of Gongxuening Capsules, and supported the research initiated by researchers on the curative effect of Qianjingteng tablets on novel coronavirus. In terms of reserves of new traditional Chinese medicine drugs, focus on the research and development of advantageous resources to incubate three key research and development projects of traditional Chinese medicine 1.1 new drugs, including Quansanqi Tablets for the treatment of symptoms related to heart stasis syndrome, the first approved clinical syndrome in my country for warming the kidney and consolidating the foundation. The new Chinese medicine Fuqi Guben Ointment, as well as the herb spray for people with COVID-19 recovery period and wind-cold-related symptoms, and the development of two classic famous prescriptions (PZ-018, PZ-019) Chinese medicine preparations simultaneously.
On the basis of consolidating the existing business, YUNNAN BAIYAO has determined the strategic goal of realizing "1 + 4 + 1" (traditional Chinese medicine + oral, skin, bone injury, female care + digitalization), optimized the industry and R & D system, and has completed operations in Beijing, Shanghai, The layout of Hong Kong, Hainan and South Korea has become an important strategic support for Baiyao to gather global resources and serve the Chinese market. It has carried out basic research, commercial development, product innovation and marketing.
At present, the leading enterprises in the traditional Chinese medicine sector in China's big health field mainly include YUNNAN BAIYAO and PIEN TZE HUANG . In the TOP20 of Chinese urban entity pharmacy end point Chinese patent medicine manufacturers in 2020, YUNNAN BAIYAO Group occupies a market share of more than 2 billion yuan, ranking fourth; PIEN TZE HUANG（Chinese：片仔癀） accounted for 1.14%, ranking 14th.
In recent research activities, YUNNAN BAIYAO said that in recent years, the company has continued to increase investment in research and development, and has made a number of important progress in research and development by combining self-research and product introduction. In 2022, the number of R&D personnel in the company exceeded 1,200, and the investment in R&D CNY 343 million, accounting for 2.68% of the company's industrial sales revenue. The R & D expense increased from CNY 174 million in 2019 to CNY 337 million in 2022.